MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
0.2047
-0.0008
-0.39%
Opening 14:04 01/23 EST
OPEN
0.2043
PREV CLOSE
0.2055
HIGH
0.2074
LOW
0.1960
VOLUME
582.30K
TURNOVER
--
52 WEEK HIGH
7.96
52 WEEK LOW
0.1830
MARKET CAP
5.49M
P/E (TTM)
-0.0676
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SYRS last week (0113-0117)?
Weekly Report · 4d ago
Weekly Report: what happened at SYRS last week (0106-0110)?
Weekly Report · 01/13 09:01
Weekly Report: what happened at SYRS last week (1230-0103)?
Weekly Report · 01/06 09:01
Weekly Report: what happened at SYRS last week (1223-1227)?
Weekly Report · 12/30/2024 09:01
Weekly Report: what happened at SYRS last week (1216-1220)?
Weekly Report · 12/23/2024 09:01
Weekly Report: what happened at SYRS last week (1209-1213)?
Weekly Report · 12/16/2024 09:01
Weekly Report: what happened at SYRS last week (1202-1206)?
Weekly Report · 12/09/2024 09:01
Weekly Report: what happened at SYRS last week (1125-1129)?
Weekly Report · 12/02/2024 09:01
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).

Webull offers Syros Pharmaceuticals Inc stock information, including NASDAQ: SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.